Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
PHIBRO ANIMAL HEALTH CORP
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-56.6% vs price
Base Case (Median)
-39.7% vs price
Bull Case (75th pct.)
20.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $25.24 | -36.6% | High (40%) |
| PE Comparable | $55.34 | 39.0% | Medium (25%) |
| Graham Number | $22.80 | -42.7% | Medium (40%) |
| EV/EBITDA | $58.16 | 46.1% | Medium (20%) |
| EV/FCF | $5.00 | -87.4% | Medium (20%) |
| Earnings Power Value | $15.43 | -61.2% | Medium (50%) |
Based on 6 out of 7 methods, PAHC appears fairly valued at the current price of $39.81. The base case fair value of $24.02 implies 39.7% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.